Tags

Type your tag names separated by a space and hit enter

Screening, diagnosis, and treatment of depression in patients with end-stage renal disease.
Clin J Am Soc Nephrol. 2007 Nov; 2(6):1332-42.CJ

Abstract

Depression is common in patients with end-stage renal disease and has been linked to increased mortality. Screening for depression in the general medical population remains controversial; however, given the high prevalence of depression and its significant impact on morbidity and mortality, a strong case for depression screening in patients with end-stage renal disease can be made. Several studies have been performed to validate the more common depression screening measures in patients with chronic kidney disease. The Beck Depression Inventory, the Hamilton Rating Scale for Depression, the Nine-Question Patient Health Questionnaire, and the Center for Epidemiologic Studies Depression Scale are some of the measures that have been used to screen for depression in patients with end-stage renal disease. Data suggest a higher Beck Depression Inventory cutoff score, of >14 to 16, will have increased positive predictive value at diagnosing depression in patients with end-stage renal disease. There are limited data on the treatment of depression in this patient population. Pharmacotherapy, including selective serotonin reuptake inhibitors, can be used if deemed clinically indicated, and no active contraindication exists. There are even fewer data to support the role of cognitive behavioral therapy, social support group interventions, and electroconvulsive therapy for treatment of depression in patients with chronic kidney disease. Larger randomized, controlled clinical trials aimed at the treatment of depression in patients with end-stage renal disease are desperately needed.

Authors+Show Affiliations

Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW, Washington, DC 20037, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17942763

Citation

Cohen, Scott D., et al. "Screening, Diagnosis, and Treatment of Depression in Patients With End-stage Renal Disease." Clinical Journal of the American Society of Nephrology : CJASN, vol. 2, no. 6, 2007, pp. 1332-42.
Cohen SD, Norris L, Acquaviva K, et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2007;2(6):1332-42.
Cohen, S. D., Norris, L., Acquaviva, K., Peterson, R. A., & Kimmel, P. L. (2007). Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clinical Journal of the American Society of Nephrology : CJASN, 2(6), 1332-42.
Cohen SD, et al. Screening, Diagnosis, and Treatment of Depression in Patients With End-stage Renal Disease. Clin J Am Soc Nephrol. 2007;2(6):1332-42. PubMed PMID: 17942763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. AU - Cohen,Scott D, AU - Norris,Lorenzo, AU - Acquaviva,Kimberly, AU - Peterson,Rolf A, AU - Kimmel,Paul L, Y1 - 2007/10/17/ PY - 2007/10/19/pubmed PY - 2007/12/6/medline PY - 2007/10/19/entrez SP - 1332 EP - 42 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 2 IS - 6 N2 - Depression is common in patients with end-stage renal disease and has been linked to increased mortality. Screening for depression in the general medical population remains controversial; however, given the high prevalence of depression and its significant impact on morbidity and mortality, a strong case for depression screening in patients with end-stage renal disease can be made. Several studies have been performed to validate the more common depression screening measures in patients with chronic kidney disease. The Beck Depression Inventory, the Hamilton Rating Scale for Depression, the Nine-Question Patient Health Questionnaire, and the Center for Epidemiologic Studies Depression Scale are some of the measures that have been used to screen for depression in patients with end-stage renal disease. Data suggest a higher Beck Depression Inventory cutoff score, of >14 to 16, will have increased positive predictive value at diagnosing depression in patients with end-stage renal disease. There are limited data on the treatment of depression in this patient population. Pharmacotherapy, including selective serotonin reuptake inhibitors, can be used if deemed clinically indicated, and no active contraindication exists. There are even fewer data to support the role of cognitive behavioral therapy, social support group interventions, and electroconvulsive therapy for treatment of depression in patients with chronic kidney disease. Larger randomized, controlled clinical trials aimed at the treatment of depression in patients with end-stage renal disease are desperately needed. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/17942763/Screening_diagnosis_and_treatment_of_depression_in_patients_with_end_stage_renal_disease_ L2 - http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17942763 DB - PRIME DP - Unbound Medicine ER -